Intelomed, Inc. CEO Jill Schiaparelli to Guest Host National Talk Radio Show at MD&M Conference in Philadelphia — iHeart Radio’s HealthTechTalk

MD&M Philadelphia Conference October 7th & 8th, Sponsored by UBM Canon MedTech World

WEXFORD, PA-(Oct 6, 2015)-InteloMed, Inc., a leading developer of non-invasive cardiovascular monitoring systems, announced today that CEO Jill Schiaparelli will guest host a special edition of HealthTechTalk Live Radio Show at the UBM MedTech World Medical Design and Manufacturing (MD&M) conference in Philadelphia on October 7th and 8th, 2015.

Live on location from MD&M Philadelphia, the four-state region’s largest medtech event, HealthTechTalk Live will interview some of the most high-profile, innovative industry and academic leaders presenting at the conference.

Serving a broad community of medtech professionals, MD&M Philadelphia delves into the latest challenges and opportunities that are impacting the industry. A multi-track conference program explores design innovations, 3D printing, new materials, packaging design and more.

About UBM Canon
UBM Canon is the leading B-to-B event producer, publisher, and digital media company for the world’s $3 trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the advanced manufacturing market and leverage our proprietary 1.3 million name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. UBM Canon is part of UBM plc (UBM.L), a global provider of media and information services for professional B-to-B communities and markets.

About HealthTechTalk Live Radio Show

HealthTechTalk Live Show broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm every Saturday. Guest host Jill Schiaparelli interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTechTalk Live, http://www.healthtechtalk.com/

About InteloMed
InteloMed is redefining the standard of care in intelligent cardiovascular monitoring in hospitals and health care facilities through its non-invasive CVInsight™ Platform. The CVInsight™ Platform provides real-time insights on the stress level of the cardiovascular system to inform clinical decisions which, as part of a well-managed care plan, may lead to earlier detection of cardiovascular decline, earlier intervention, decreased hospitalization and improved patient outcomes. The CVInsight™ Platform has functionality in hospital and outpatient settings and has clinical applications in multiple areas including hemodialysis, heart failure, and the surgical continuum. InteloMed is headquartered in Wexford, PA. For more information, visit us at www.InteloMed.com.

Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.

A 1800PublicRelations.com PR Event…

PR / Media
Matthew Bird
President
1-800-PublicRelations, Inc.
646.401.4499
matt.bird@1800pr.com

CEO Gregory D. Cash of BioSig Technologies, Inc. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “HealthTech Talk”

Live Interview to Air on April 4th 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

LOS ANGELES, CA–(Apr 3, 2015) – BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace, announced today that Chief Executive Officer (CEO), President, and Director Gregory D. Cash will be interviewed live on iHeart Radio’s HealthTech Talk hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive interview, Mr. Cash will discuss its product PURE EP™ System which EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide stream are below.

Date: April 4, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About BioSig Technologies, Inc.
BioSig Technologies, Inc. (BSGM) is a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP™ System.

PURE EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. It is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and provide guidance in identifying ablation targets — areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). BioSig believes this information is not easily obtained, if at all, from any other EP equipment in the market today.

These ablation procedures treat cardiac arrhythmias, which are broadly defined as a set of conditions in which the electrical activity of the heart is irregular, or faster or slower than normal. This type of heart disease afflicts 14.4 million Americans, or one in 18. Two of the most prevalent and deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT).

About CEO, President, and Director Gregory D. Cash
Greg Cash is an experienced executive and a seasoned industry veteran. He has over 30 years of business experience and has been chief executive officer of several companies, both public and privately held, as well as run global business units of larger companies.

Prior to joining BioSig, Mr. Cash was President and CEO of Argent International, a life sciences consulting firm. Previous positions include President and Chief Executive Officer of NeuroTherm, Inc., President and Chief Executive Officer, as well as a director of HeartSine Technologies, Inc., President, Vascular Therapy and New Businesses for Sorin Group based in Milan, Italy, President and Chief Executive Officer and a director of Vasomedical, Inc. a NASDAQ traded public company, Corporate Vice President, Datascope Corporation, and President of its subsidiary, InterVascular, Inc., President and Chief Operating Officer of Eminent Technology Partners and Chief Executive Office of its subsidiary, Eminent Research Systems, Vice President and General Manager, Vascular Therapies, for U.S. Surgical Corporation and spent five years with Boston Scientific Corporation, ultimately as Vice President, Cardiology Sales and Marketing, Europe. He began his career at Medtronic, Inc., where he served 14 years in increasingly senior sales and marketing positions.

Mr. Cash has lived and worked as an expatriate in London, England, Hong Kong, Paris, France and Milan, Italy and speaks French, German and Italian. He holds a B.A. in International Marketing and Business Administration from the College of St. Thomas in St. Paul, Minnesota.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

1800PublicRelations.com PR Event…

Interview Press / Media
Matthew Bird
President
1-800-PublicRelations, Inc.
917.409.8211
matt.bird@1800pr.com
www.1800pr.com

Chief Medical Officer & Co-Founder Katrina Firlik, MD of HealthPrize Technologies to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “HealthTech Talk”

Live Interview to Air on March 28th 2015, Hosted by Ben Chodor, 3:30pm ET/12:30pm PT/2:30pm CT

NORWALK, CT–(Mar 27, 2015) – HealthPrize Technologies, a digital health leader in patient engagement and medication adherence solutions, announced today that Chief Medical Officer and Co-Founder Katrina Firlik, MD will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:30pm ET. In this exclusive interview, Dr. Firlik will discuss their customizable platform, which combines incentives, behavioral economics, gamification and education to motivate patients to take charge of their own health and wellness. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: March 28, 2015 

Start Time: 3:30pm ET | 12:30pm PT | 2:30pm CT (U.S.)

Network: iHeart Radio/ Clear Channel

Station: 640 WGST AM

Show: Health Tech Talk Live

Host: Ben Chodor

iHeart Radio Live Stream: CLICK HERE

About HealthPrize Technologies
HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient engagement platform provides an innovative approach to addressing the problem of medication non-adherence with an online and mobile-based program that is fun, educational and rewarding. The HealthPrize system leverages gaming dynamics, behavioral economics and proven concepts from consumer marketing to maximize engagement while also using education to strengthen the intrinsic motivation required for long-term persistence to prescribed medications. For more information, visit www.healthprize.com and follow us on Twitter at @HealthPrize.

About Chief Medical Officer and Co-Founder Katrina Firlik, MD
Prior to founding HealthPrize Technologies, Katrina was a neurosurgeon in private practice at Greenwich Hospital in Greenwich, Connecticut, and on the clinical faculty at Yale University School of Medicine. In addition to her scientific publications, Katrina is the author of Another Day in the Frontal Lobe: A Brain Surgeon Exposes Life on the Inside, published by Random House and reviewed by The New York Times, The Los Angeles Times, and O Magazine. She has appeared on CNN, Fox, and MSNBC as a commentator on a variety of medical issues. She is also an inventor of a brain stimulation device designed to enhance recovery after stroke. Katrina completed her undergraduate studies at Cornell University with a major in cultural anthropology. She attended medical school at Case Western Reserve University, and did her neurosurgery residency at the University of Pittsburgh, one of the largest neurosurgery centers in the country, where she was the first woman accepted to the program. Katrina also completed a specialty fellowship in epilepsy surgery at Yale University. She is a member of the HealthPrize Board of Directors.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Interview Press/ Media
Matthew Bird
President
1-800-PublicRelations, Inc.
917.409.8211
matt.bird@1800pr.com
www.1800pr.com

CEO Nicholas U. Spring ReliefBand® Medical Technologies LLC to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air on March 14th 2015, Hosted by Ben Chodor, 3:30pm ET/12:30pm PT/2:30pm CT

CHICAGO, IL–(Mar 13, 2015) – ReliefBand® Medical Technologies LLC, a company passionately devoted to developing FDA cleared and clinically tested digital, wearable devices that stop both nausea and vomiting, announced today that member of the Board of Directors and Chief Executive Officer (CEO) Nicholas (Nick) U. Spring will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:30pm ET. In this exclusive interview, Mr. Spring will discuss how the wearable devices are not only easy to use and generally work within minutes of application, but are comfortable and have simple to replace batteries. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: March 14, 2015
Start Time: 3:30pm ET | 12:30pm PT | 2:30pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE 

About Reliefband® Medical Technologies LLC: ReliefBand Medical Technologies is a Neurotechnology (software and data) and marketing company that provides leading edge personalized medical treatments, which put patients in control of their treatment and their lives because our proprietary, FDA cleared, wearable waveform technology is non-invasive, highly effective and precisely controlled by the user. It can be turned off, on, up or down to suit individual needs.

About Director & CEO Nicholas (Nick) U. Spring: Nicholas (Nick) U. Spring is an experienced CEO, successful executive and entrepreneur with a track record of company startups, development and exits in the OTC and Rx Pharmaceutical markets. Topaz Pharmaceuticals Inc., the company that he founded in 2005, was acquired by Sanofi Pasteur in 2011. He personally led Topaz through multiple rounds of financing, R&D (pre-clinical to FDA submission) as CEO & President and Board Member. The FDA approved Sklice®, the product that he founded the company upon, on Feb 7, 2012 — a major achievement for a small startup company. Nick has worked closely with digital healthcare companies as well as middle to big Pharma companies advising them at the highest level on business strategies and life cycle management. Prior to that he enjoyed a global career at Merck as a senior manager in many countries worldwide. Nick is also a Business Adviser with the Science Center of Philadelphia’s QED program for innovation, an Adjunct Professor of Pharmaceutical and Healthcare business at the University of Sciences, Philadelphia and was recently elected to the Commercialization Advisory Board of Penn State College of Medicine.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

CEO & Founder Cort Smith of Da Vinci Vaporizer to Be Interviewed Live on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air on March 14th, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

LAS VEGAS, NV–(Mar 13, 2015) – Da Vinci Vaporizer, a company that manufactures and retails advanced vaporizer products and accessories, announced today that Chief Executive Officer (CEO) and Founder Cort Smith will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive interview, Mr. Smith will discuss the portability, reliability, function, innovation and service, all key factors, which contribute to each and every one of their products. We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide steam are below.

Date: March 14, 2015
Start Time: 3:30pm ET | 12:30pm PT | 2:30pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About Da Vinci Vaporizer
Our mission is to bring innovative products from mind to market. Da Vinci Vaporizer is the most notorious of our brands that is held by East West Bridge, the mother ship. Alongside Da Vinci, we build products in the automobile accessory market, the human mobility market and the durable medical goods industry. Outside of our own brands, we build over 400 products for other US companies that utilize our presence in China. We have over 100 people in the organization in 3 cities globally.

About CEO and Founder Cort Smith
Cort Smith grew up in the Bay Area CA with a strong interest in technology and how things are put together. In 1988, Cort moved to Taiwan where he set up his first international business of Bungee Jumping. By 1995 he began building bungee towers all over China and quickly developed the language and skills needed to work with Chinese manufacturers. While in China Cort produced China’s first X games and worked alongside many multi-national companies. By 2002 Cort returned to the US and settled in Las Vegas where he continues to create new products and manage an “extremely” vibrant business.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm ET every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

1800PublicRelations.com PR Event…

iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM Featured Doctors Mobile Healthcare International on “HealthTech Talk Live”

Interview Archive Now Available — March 16, 2015

CORAL SPRINGS, FL–(Mar 17, 2015) – “HealthTech Talk Live,” hosted by Ben Chodor and broadcasted every Saturday from 3-4pm ET on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM, is proud to announce that the interview archive of Doctors Mobile Healthcare International’s CEO George England is now available. Doctors Mobile Healthcare International (OTCBB: DMHI) is a company dedicated to help surgeons, medical institutions and medical vendors improve clinical and financial outcomes by utilizing their intuitive mobile healthcare platform that focuses on these core values: increasing accountability, improving clinical outcomes, driving revenue, and saving time and money. In this captivating double-segment interview, Mr. England discussed why it’s critically important to keep everyone accountable among all the stakeholders that deliver care to patients especially around the surgical space.

US. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen to the link below:

NOW AVAILABLE: PLAY INTERVIEW ARCHIVE
Show Details:
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor

Interview Highlights:

  • Learn how DMHI continues to develop and utilize their Virtual Physicians Network healthcare mobile platform
  • How can technology reduce unwarranted treatment variations and reduce exorbitant healthcare cost
  • Collecting and analyzing clinical outcomes on all surgical patients and not just those enrolled in studies. DMHI effectively collects and analyzes feedback from all the stakeholders’ in the surgical process
  • Continue to keep patient privacy a focus as technology continues to push the reliability of everyone’s privacy

About Doctors Mobile Healthcare International
Doctors Mobile Healthcare International is a public company dedicated to help surgeons, medical institutions and medical vendors improve clinical and financial outcomes by utilizing our intuitive mobile healthcare platform that focuses on these core values: Increasing Accountability, Improving Clinical Outcomes, Driving Revenue, and Saving Time and Money.

About CEO George England
Mr. England is currently the CEO of DHMI with over 26 years of experience as a healthcare entrepreneur and executive. His professional background is firmly rooted in the healthcare industry with over 26 years of consulting, building businesses and working with national healthcare companies such as Synthes, Osteotech, K2M and Nuvasive. Mr. England has also consulted with several national start-up companies in the healthcare vertical with a focus on fundraising and corporate development.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

1800PublicRelations.com PR Event…

iHeart Radio’s “HealthTech Talk” Show to Feature MYOS Corporation’s Ingredient Fortetropin™ in Exclusive Interview With Company Chairman

Dr. Robert Hariri to Be Interviewed by Ben Chodor on March 7, 2015 at 3:00pm ET/12:00pm PT/2:00pm CT

CEDAR KNOLLS, NJ–(Mar 6, 2015) – MYOS Corporation (“MYOS” or the “Company”) (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that its Chairman of the Board, Dr. Robert J. Hariri, will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios — 640 WGST AM tomorrow, at 3:00pm ET.

In this exclusive interview, Dr. Hariri will discuss the Company’s all-natural ingredient, Fortetropin™, the first clinically demonstrated myostatin inhibitor, and soon-to-be launched product line RE, the Company’s 2014 milestones and touch on MYOS’s 2015 outlook and the recent outspoken celebrity attention MYOS has been garnering from Justin Bieber and the world’s strongest man. Fortetropin™ is manufactured to optimize biological activity to build healthy lean muscle. MYOS believes Fortetropin™ has the potential to redefine existing standards for muscle health and human longevity.

MYOS encourages all shareholders, analysts, industry professionals and interested parties to tune in live to the interview with Dr. Hariri. The details and link to iHeart Radio’s live worldwide stream are below.

Date: March 7, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information about please visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Show
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

About Dr. Robert Hariri
Dr. Robert Hariri is a surgeon, biomedical scientist and highly successful serial entrepreneur in two technology sectors: biomedicine and aerospace. The Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics, one of the world’s largest human cellular therapeutics companies, Dr. Hariri has pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering. In addition to his role at Celgene Cellular Therapeutics, Dr. Hariri is also Vice-Chairman & Co-Founder of Human Longevity, Inc. (HLI).

His activities and experience includes academic neurosurgeon at Cornell, businessman, military surgeon and aviator and aerospace innovator. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumor necrosis factor).

Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011, The Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to biomedicine and aviation. Dr. Hariri also serves on numerous Boards of Directors including Myos Corporation and Provista Diagnostics. Dr. Hariri is an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine and a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center and has been appointed Commissioner of Cancer Research by NJ Governor Christie. Dr. Hariri is also a member of the Board of Trustees of the J. Craig Venter Institute.

A jet-rated commercial pilot with thousands of hours of flight time in over 60 different military and civilian aircraft, Dr. Hariri has also produced several feature films as well as documentaries on global societal issues.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as “The Muscle Company,”™ visit www.myoscorp.com.

The Company’s first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.comwww.bodybuilding.comwww.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our products, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully develop and launch our own core branded products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to enter into strategic relationships with new distributors, the ability to comply with NASDAQ’s continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

1800PublicRelations.com PR Event…

Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live” on February 14, 2015

Live Interview Airs on “Health Tech Talk Live,” Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

ATLANTA, GA–(Feb 13, 2015) – Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel®, the company’s development of the world’s first antiviral condom (the VivaGel® condom) which was recently launched in Australia by Starpharma’s partner, Ansell. Dr Fairley will also talk about Starpharma’s current US Phase III clinical trials of VivaGel® for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company’s improved version of cancer drug docetaxel (Taxotere). The Company’s product, DEP™ docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP™ docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere® and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup®) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 14, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers — a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer. VivaGel® formulated as a mucoadhesive gel and delivered vaginally is under clinical development for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate license agreements with Ansell Limited (ASX: ANN) and Okamoto Industries Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®) which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals, Starpharma has a series of partnerships with leading industry players, as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

Starpharma’s headquarters and research facilities are located in Melbourne, Australia. Starpharma principally consists of two operating companies, Starpharma Pty Ltd in Australia and Dendritic Nanotechnologies, Inc. in USA, both with a comprehensive intellectual property portfolio.

Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX: SPHRY). OTCQX is the premium tier of the US Over-the-Counter (OTC) marketplace, providing non-US companies with a visible cross-listing to access US investors, without the duplicative regulatory costs required of listing on a traditional US exchange.

About CEO Dr. Jackie Fairley B.Sc., B.V.Sc. (Hons), MBA

Jackie Fairley has 25 years of operational experience in the pharmaceutical and biotechnology industries working as a CEO since 2000. Prior to that she held business development, licensing and general management roles with companies including CSL and Faulding (now Hospira).

In 2006, Jackie was appointed CEO of ASX-listed biotechnology company Starpharma Holdings. Under her leadership, the company has been promoted to the ASX300, has developed several new and valuable commercial applications for its proprietary polymer technology and signed a number of strategically important commercial deals with companies including Astra Zeneca, Okamoto and Ansell. Starpharma has also significantly strengthened its institutional shareholder base, attracting investment from major European, US and Asian funds.

Jackie holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School, where as top student in her final year, she was the recipient of the prestigious Clemenger Medal. Jackie is also a Graduate of the Australian Institute of Company Directors.

In addition to her role at Starpharma, Jackie has served on the Board of the Melbourne Business School since 2010 and sits on the Investment Committee of Mark Carnegie’s Innovation Fund. She also sits on a number of specialist Government advisory committees.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air on February 28th, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

HAYWARD, CA–(Feb 27, 2015) – Aradigm Corporation (NASDAQ: ARDM), a company actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease, announced today that President and Chief Executive Officer (CEO) Dr. Igor Gonda, Ph.D. will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive double-segment interview, Dr. Gonda will discuss how the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products like AERx®, a pulmonary delivery platform.

Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 28, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE 

About Aradigm Corporation
Aradigm is actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease.

Since 1991, the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products. This team for example, pioneered the AERx® pulmonary delivery platform that was tested in thousands of patients with drugs and biologics including insulin, fentanyl, erythropoietin and nicotine. With the depth of experience and expertise in inhalation delivery, Aradigm is uniquely positioned to develop a portfolio of its own products to treat patients with severe respiratory diseases. The current pipeline includes an inhaled antibiotic being developed for the treatment of bronchiectasis*, cystic fibrosis and for biodefense, and inhaled nicotine for smoking cessation.

About President and CEO Dr. Igor Gonda, Ph.D.
Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

1800PublicRelations.com PR Event…

CEO & Chairman Ted William Karkus of ProPhase Labs, Inc. to Be Interviewed Live on Clear Channel – iHeart Business Talk Radio’s “Health Tech Talk Live”

Live Interview Airs Saturday, February 28th, 2015, 3:00pm ET/12:00pm PT/2:00pm CT

DOYLESTOWN, PA–(Feb 27, 2015) – ProPhase Labs, Inc. (NASDAQ: PRPH), a company that engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public, announced today that CEO & Chairman Ted William Karkus will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive 2-segment interview, Mr. Karkus will discuss the research and development of over-the-counter (OTC) drugs, natural base health products with supplements, personal care and cosmeceutical products. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 28, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About ProPhase Labs, Inc.
ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® Cold Remedy brand as well as other cold relief products. Cold-EEZE®Cold Remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE® Cold Remedy customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE®Cold Remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at www.ProPhaseLabs.com.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Forward Looking Information
Except for the historical information contained herein or discussed on air on February 28, 2015, this document and our on-air discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

iheartradioiheartradioiheartradioiheartradioiheartradioiheartradioiheartradio